

Supplementary Table. Observed incident cases (O) and standardized incidence ratios (SIR) with 95% confidence intervals (CI) of selected SPMs after an initial diagnosis of DLBCL, California, 1989-2012

		All Solid Tumor		Lung		Prostate		Breast		Colorectal		Urinary Bladder		Melanoma of the Skin	
		O	SIR (95% CI)	O	SIR (95% CI)	O	SIR (95% CI)	O	SIR (95% CI)	O	SIR (95% CI)	O	SIR (95% CI)	O	SIR (95% CI)
All	Pre-Rituximab	495	1.15 (1.05-1.26)	88	1.25 (1.00-1.54)	88	0.94 (0.75-1.16)	69	1.25 (0.98-1.59)	59	1.28 (0.97-1.65)	25	1.01 (0.65-1.49)	18	1.22 (0.72-1.93)
	Post-Rituximab	773	1.08 (1.01-1.16)	129	1.23 (1.03-1.46)	121	0.87 (0.72-1.04)	76	0.84 (0.66-1.05)	64	1.00 (0.77-1.27)	51	1.14 (0.85-1.50)	50	1.23 (0.91-1.62)
Age at diagnosis															
<65	Pre-Rituximab	175	1.28 (1.10-1.49)	39	1.87 (1.33-2.55)	21	0.72 (0.45-1.10)	23	1.08 (0.69-1.63)	15	1.25 (0.7-2.06)	12	1.99 (1.03-3.48)	8	1.29 (0.56-2.55)
	Post-Rituximab	310	1.25 (1.11-1.39)	51	1.94 (1.45-2.55)	54	0.92 (0.69-1.20)	33	0.88 (0.61-1.24)	18	0.92 (0.55-1.46)	11	1.08 (0.54-1.93)	24	1.58 (1.01-2.35)
65+	Pre-Rituximab	320	1.09 (0.97-1.21)	49	0.99 (0.73-1.31)	67	1.04 (0.81-1.32)	46	1.36 (1.00-1.82)	44	1.29 (0.94-1.73)	13	0.69 (0.37-1.18)	10	1.17 (0.56-2.15)
	Post-Rituximab	463	1.00 (0.91-1.09)	78	0.99 (0.79-1.24)	67	0.83 (0.64-1.05)	43	0.81 (0.59-1.09)	46	1.03 (0.75-1.37)	40	1.16 (0.83-1.58)	26	1.02 (0.67-1.49)
Sex															
Male	Pre-Rituximab	287	1.12 (0.99-1.26)	47	1.11 (0.82-1.48)	88	0.94 (0.75-1.16)	4	7.11 (1.94-18.19)	36	1.35 (0.95-1.87)	21	1.07 (0.66-1.63)	14	1.40 (0.76-2.35)
	Post-Rituximab	456	1.09 (0.99-1.20)	74	1.27 (0.99-1.59)	121	0.87 (0.72-1.04)	<3	1.89 (0.23-6.83)	36	0.99 (0.69-1.37)	37	1.04 (0.73-1.44)	34	1.21 (0.84-1.69)
Female	Pre-Rituximab	208	1.19 (1.04-1.37)	41	1.47 (1.05-1.99)	0		65	1.19 (0.92-1.52)	23	1.17 (0.74-1.76)	4	0.78 (0.21-2.01)	4	0.85 (0.23-2.17)
	Post-Rituximab	317	1.07 (0.96-1.20)	55	1.19 (0.90-1.55)	0		74	0.83 (0.65-1.04)	28	1.00 (0.67-1.45)	14	1.54 (0.84-2.58)	16	1.27 (0.73-2.07)
Race/ethnicity															
Non-Hispanic White	Pre-Rituximab	400	1.18 (1.06-1.30)	76	1.29 (1.02-1.62)	68	0.98 (0.76-1.24)	56	1.25 (0.95-1.63)	45	1.23 (0.89-1.64)	23	1.06 (0.67-1.59)	18	1.39 (0.83-2.20)
	Post-Rituximab	559	1.14 (1.04-1.23)	104	1.31 (1.07-1.59)	85	0.99 (0.79-1.22)	51	0.80 (0.59-1.05)	45	1.05 (0.77-1.41)	39	1.11 (0.79-1.52)	45	1.38 (1.01-1.85)
Non-Hispanic Black	Pre-Rituximab	13	0.85 (0.45-1.46)	3	1.10 (0.23-3.22)	3	0.68 (0.14-1.98)	<3	0.62 (0.02-3.45)	0		0		0	
	Post-Rituximab	25	0.99 (0.64-1.46)	3	0.76 (0.16-2.22)	7	1.15 (0.46-2.36)	4	1.14 (0.31-2.92)	<3	0.80 (0.10-2.90)	<3	1.17 (0.03-6.49)	<3	16.10 (0.41-89.69)
Hispanic	Pre-Rituximab	49	1.36 (1.01-1.80)	5	1.18 (0.38-2.77)	9	1.23 (0.56-2.33)	7	1.39 (0.56-2.86)	8	2.14 (0.93-4.23)	<3	0.78 (0.02-4.34)	0	
	Post-Rituximab	108	1.19 (0.98-1.44)	10	1.02 (0.49-1.87)	17	0.96 (0.56-1.54)	12	1.02 (0.53-1.78)	13	1.43 (0.76-2.44)	3	0.80 (0.17-2.35)	4	3.35 (0.91-8.57)
Asian/Pacific Islander	Pre-Rituximab	31	1.26 (0.86-1.79)	4	1.01 (0.27-2.57)	8	1.72 (0.74-3.38)	5	2.03 (0.66-4.73)	4	1.17 (0.32-3.00)	<3	1.07 (0.03-5.98)	0	
	Post-Rituximab	76	1.35 (1.06-1.69)	12	1.32 (0.68-2.31)	11	1.31 (0.65-2.34)	8	1.07 (0.46-2.10)	4	0.56 (0.15-1.43)	6	2.61 (0.96-5.68)	0	
Treatment															
Chemo yes	Pre-Rituximab	400	1.19 (1.08-1.32)	66	1.19 (0.92-1.51)	70	0.97 (0.76-1.23)	53	1.22 (0.92-1.60)	43	1.21 (0.87-1.62)	24	1.25 (0.80-1.86)	17	1.48 (0.86-2.37)
	Post-Rituximab	635	1.11 (1.03-1.20)	104	1.23 (1.01-1.49)	100	0.91 (0.74-1.11)	63	0.86 (0.66-1.10)	54	1.05 (0.79-1.37)	42	1.19 (0.85-1.60)	42	1.33 (0.96-1.79)
Chemo no	Pre-Rituximab	95	1.00 (0.81-1.22)	22	1.49 (0.93-2.26)	18	0.84 (0.50-1.33)	16	1.37 (0.78-2.23)	16	1.52 (0.87-2.46)	<3	0.18 (0.00-0.99)	<3	0.31 (0.01-1.70)
	Post-Rituximab	138	0.97 (0.82-1.15)	25	1.24 (0.80-1.82)	21	0.71 (0.44-1.09)	13	0.76 (0.40-1.30)	10	0.78 (0.38-1.44)	9	0.98 (0.45-1.86)	8	0.89 (0.38-1.75)
Rad yes	Pre-Rituximab	163	1.18 (1.01-1.38)	22	0.97 (0.61-1.47)	32	1.09 (0.74-1.53)	24	1.40 (0.90-2.08)	22	1.48 (0.93-2.24)	5	0.62 (0.20-1.44)	7	1.43 (0.58-2.96)
	Post-Rituximab	184	1.02 (0.88-1.18)	24	0.90 (0.58-1.34)	28	0.85 (0.57-1.23)	18	0.76 (0.45-1.20)	19	1.16 (0.70-1.81)	12	1.07 (0.55-1.86)	16	1.57 (0.90-2.55)
Rad no	Pre-Rituximab	332	1.13 (1.01-1.26)	66	1.39 (1.07-1.76)	56	0.87 (0.66-1.13)	45	1.19 (0.87-1.59)	37	1.18 (0.83-1.63)	20	1.20 (0.73-1.85)	11	1.12 (0.56-2.00)
	Post-Rituximab	589	1.10 (1.02-1.20)	105	1.34 (1.10-1.63)	93	0.87 (0.70-1.07)	58	0.87 (0.66-1.12)	45	0.94 (0.69-1.26)	39	1.17 (0.83-1.60)	34	1.11 (0.77-1.56)
Neighborhood SES															
Low	Pre-Rituximab	243	1.12 (0.98-1.27)	42	1.20 (0.87-1.63)	45	0.98 (0.71-1.31)	35	1.23 (0.85-1.70)	31	1.31 (0.89-1.87)	13	1.08 (0.57-1.84)	8	1.14 (0.49-2.25)
	Post-Rituximab	345	1.04 (0.93-1.15)	62	1.31 (1.00-1.68)	48	0.74 (0.55-0.98)	33	0.75 (0.52-1.06)	23	0.76 (0.48-1.14)	26	1.34 (0.88-1.97)	20	1.15 (0.70-1.78)
High	Pre-Rituximab	252	1.18 (1.04-1.34)	46	1.30 (0.95-1.74)	43	0.90 (0.65-1.22)	34	1.29 (0.89-1.80)	28	1.24 (0.82-1.79)	12	0.94 (0.49-1.64)	10	1.29 (0.62-2.37)
	Post-Rituximab	406	1.12 (1.01-1.23)	63	1.15 (0.88-1.47)	70	0.99 (0.77-1.24)	42	0.95 (0.68-1.28)	39	1.2 (0.85-1.64)	24	0.99 (0.64-1.48)	29	1.30 (0.87-1.87)
Latency															
1 to 3 years	Pre-Rituximab	186	1.02 (0.88-1.18)	29	0.97 (0.65-1.39)	34	0.83 (0.57-1.15)	22	0.96 (0.60-1.46)	26	1.33 (0.87-1.95)	12	1.16 (0.60-2.02)	7	1.18 (0.48-2.44)
	Post-Rituximab	295	1.05 (0.94-1.18)	47	1.14 (0.84-1.52)	49	0.85 (0.63-1.12)	23	0.66 (0.42-1.00)	28	1.09 (0.73-1.58)	18	1.04 (0.62-1.64)	15	0.97 (0.54-1.60)
3 to 5 years	Pre-Rituximab	133	1.17 (0.98-1.38)	21	1.13 (0.70-1.73)	32	1.28 (0.87-1.80)	20	1.39 (0.85-2.14)	14	1.15 (0.63-1.92)	6	0.91 (0.34-1.99)	3	0.77 (0.16-2.26)
	Post-Rituximab	199	1.03 (0.89-1.18)	34	1.20 (0.83-1.67)	30	0.79 (0.53-1.13)	23	0.94 (0.59-1.41)	15	0.86 (0.48-1.41)	9	0.75 (0.34-1.42)	15	1.37 (0.76-2.25)
5 to 7 years	Pre-Rituximab	85	1.18 (0.94-1.46)	16	1.35 (0.77-2.20)	9	0.61 (0.28-1.15)	17	1.80 (1.05-2.88)	11	1.41 (0.70-2.52)	<3	0.48 (0.06-1.72)	5	1.92 (0.62-4.49)
	Post-Rituximab	142	1.11 (0.93-1.30)	19	1.01 (0.61-1.57)	25	1.04 (0.67-1.53)	15	0.90 (0.50-1.48)	14	1.21 (0.66-2.04)	14	1.74 (0.95-2.91)	8	1.08 (0.46-2.12)
7+ years	Pre-Rituximab	91	1.47 (1.19-1.81)	22	2.22 (1.39-3.35)	13	1.04 (0.55-1.78)	10	1.22 (0.58-2.23)	8	1.20 (0.52-2.36)	5	1.37 (0.44-3.19)	3	1.27 (0.26-3.72)
	Post-Rituximab	137	1.23 (1.04-1.46)	29	1.79 (1.20-2.57)	17	0.86 (0.50-1.38)	15	1.03 (0.58-1.70)	7	0.73 (0.29-1.50)	10	1.38 (0.66-2.54)	12	1.75 (0.90-3.05)
Stage of initial DLBCL															
Local/Regional	Pre-Rituximab	290	1.11 (0.98-1.24)	39	0.91 (0.65-1.24)	54	0.97 (0.73-1.26)	48	1.44 (1.06-1.91)	34	1.19 (0.83-1.67)	12	0.78 (0.40-1.37)	13	1.45 (0.77-2.48)
	Post-Rituximab	379	1.02 (0.92-1.13)	59	1.08 (0.82-1.39)	65	0.92 (0.71-1.18)	37	0.77 (0.54-1.06)	26	0.77 (0.50-1.12)	26	1.12 (0.73-1.64)	27	1.29 (0.85-1.87)
Advanced	Pre-Rituximab	163	1.30 (1.11-1.52)	37	1.77 (1.24-2.44)	29	1.11 (0.74-1.59)	16	0.97 (0.55-1.57)	21	1.58 (0.98-2.42)	10	1.41 (0.68-2.60)	5	1.19 (0.39-2.77)
	Post-Rituximab	340	1.20 (1.08-1.34)	58	1.38 (1.05-1.78)	49	0.86 (0.64-1.14)	34	0.96 (0.67-1.35)	34	1.35 (0.94-1.89)	24	1.36 (0.87-2.02)	21	1.34 (0.83-2.04)

Supplementary Table (cont.). Observed incident cases (O) and standardized incidence ratios (SIR) with 95% confidence intervals (CI) of selected SPMs after an initial diagnosis of DLBCL, California, 1989-2012

		Head and Neck		Liver		Pancreas		Kidney		Thyroid		AML		Hodgkin's lymphoma	
		O	SIR (95% CI)	O	SIR (95% CI)	O	SIR (95% CI)	O	SIR (95% CI)	O	SIR (95% CI)	O	SIR (95% CI)	O	SIR (95% CI)
All	Pre-Rituximab	15	0.98 (0.55-1.61)	10	1.42 (0.68-2.62)	15	1.26 (0.71-2.08)	6	0.60 (0.22-1.32)	<3	0.66 (0.08-2.37)	16	4.39 (2.51-7.13)	12	10.38 (5.36-18.13)
	Post-Rituximab	31	1.26 (0.86-1.79)	30	1.66 (1.12-2.37)	22	0.93 (0.59-1.41)	23	0.95 (0.60-1.42)	23	2.27 (1.44-3.41)	59	8.70 (6.62-11.22)	16	7.99 (4.57-12.98)
Age at diagnosis															
<65	Pre-Rituximab	4	0.65 (0.18-1.66)	6	2.49 (0.92-5.43)	4	1.37 (0.37-3.51)	3	0.82 (0.17-2.40)	<3	1.12 (0.14-4.04)	7	6.79 (2.73-13.99)	8	12.84 (5.54-25.30)
	Post-Rituximab	15	1.46 (0.82-2.40)	18	2.44 (1.45-3.86)	7	1.14 (0.46-2.34)	11	1.14 (0.57-2.04)	18	2.94 (1.74-4.65)	27	14.48 (9.54-21.07)	11	11.18 (5.58-20.00)
65+	Pre-Rituximab	11	1.2 (0.6-2.15)	4	0.86 (0.24-2.21)	11	1.23 (0.61-2.20)	3	0.48 (0.10-1.40)	0		9	3.45 (1.58-6.54)	4	7.54 (2.06-19.31)
	Post-Rituximab	16	1.12 (0.64-1.82)	12	1.12 (0.58-1.96)	15	0.86 (0.48-1.42)	12	0.82 (0.42-1.43)	5	1.25 (0.40-2.91)	32	6.51 (4.45-9.18)	5	4.92 (1.60-11.48)
Sex															
Male	Pre-Rituximab	10	0.90 (0.43-1.66)	8	1.83 (0.79-3.60)	8	1.28 (0.55-2.52)	5	0.75 (0.24-1.75)	<3	0.91 (0.02-5.07)	8	3.48 (1.50-6.87)	7	9.86 (3.97-20.32)
	Post-Rituximab	24	1.32 (0.84-1.96)	20	1.67 (1.02-2.58)	14	1.13 (0.62-1.89)	16	0.98 (0.56-1.59)	7	2.02 (0.81-4.15)	30	7.33 (4.94-10.46)	7	5.71 (2.30-11.77)
Female	Pre-Rituximab	5	1.18 (0.38-2.76)	<3	0.75 (0.09-2.72)	7	1.24 (0.50-2.56)	<3	0.31 (0.01-1.70)	<3	0.51 (0.01-2.86)	8	5.94 (2.56-11.70)	5	11.20 (3.64-26.15)
	Post-Rituximab	7	1.10 (0.44-2.27)	10	1.64 (0.79-3.01)	8	0.72 (0.31-1.42)	7	0.88 (0.35-1.81)	16	2.41 (1.38-3.91)	29	10.78 (7.22-15.48)	9	11.59 (5.30-22.01)
Race/ethnicity															
Non-Hispanic White	Pre-Rituximab	11	0.89 (0.44-1.59)	5	1.31 (0.42-3.05)	11	1.19 (0.59-2.12)	6	0.78 (0.28-1.69)	2	0.96 (0.12-3.47)	11	3.74 (1.86-6.68)	8	9.04 (3.90-17.82)
	Post-Rituximab	26	1.45 (0.95-2.12)	13	1.54 (0.82-2.63)	15	0.92 (0.52-1.52)	14	0.86 (0.47-1.43)	15	2.39 (1.34-3.93)	41	8.49 (6.09-11.52)	8	5.97 (2.58-11.77)
Non-Hispanic Black	Pre-Rituximab	<3	1.62 (0.04-9.05)	<3	3.78 (0.1-21.05)	0		0		0		0		<3	45.22 (5.48-163.35)
	Post-Rituximab	0		0		<3	1.06 (0.03-5.90)	<3	0.99 (0.03-5.54)	1	3.22 (0.08-17.93)	<3	10.42 (1.26-37.65)	<3	12.16 (0.31-67.76)
Hispanic	Pre-Rituximab	3	2.74 (0.57-8.01)	<3	0.73 (0.02-4.07)	4	3.17 (0.86-8.13)	0		0		<3	6.42 (0.78-23.18)	<3	6.14 (0.16-34.2)
	Post-Rituximab	<3	0.37 (0.01-2.06)	12	2.58 (1.34-4.51)	5	1.40 (0.45-3.27)	7	1.55 (0.62-3.20)	2	1.10 (0.13-3.97)	10	11.21 (5.38-20.62)	6	15.53 (5.70-33.79)
Asian/Pacific Islander	Pre-Rituximab	0		3	2.01 (0.42-5.88)	0		0		0		3	12.44 (2.57-36.35)	<3	21.61 (0.55-120.42)
	Post-Rituximab	4	2.42 (0.66-6.19)	5	1.40 (0.45-3.26)	<3	0.44 (0.01-2.47)	<3	0.63 (0.02-3.53)	5	3.73 (1.21-8.70)	6	9.24 (3.39-20.12)	<3	9.51 (0.24-52.99)
Treatment															
Chemo yes	Pre-Rituximab	14	1.15 (0.63-1.93)	8	1.45 (0.63-2.87)	14	1.53 (0.84-2.57)	5	0.64 (0.21-1.48)	<3	0.80 (0.10-2.90)	14	4.93 (2.70-8.28)	9	9.56 (4.37-18.14)
	Post-Rituximab	28	1.41 (0.94-2.04)	22	1.50 (0.94-2.27)	19	1.00 (0.60-1.57)	18	0.91 (0.54-1.44)	20	2.37 (1.45-3.66)	48	8.80 (6.49-11.67)	14	8.52 (4.66-14.30)
Chemo no	Pre-Rituximab	<3	0.32 (0.01-1.78)	<3	1.31 (0.16-4.72)	<3	0.37 (0.01-2.04)	<3	0.48 (0.01-2.70)	0		<3	2.48 (0.30-8.97)	3	14.01 (2.89-40.95)
	Post-Rituximab	3	0.63 (0.13-1.85)	8	2.36 (1.02-4.64)	3	0.65 (0.13-1.90)	5	1.11 (0.36-2.59)	3	1.79 (0.37-5.22)	11	8.27 (4.13-14.8)	<3	5.57 (0.67-20.11)
Rad yes	Pre-Rituximab	9	1.80 (0.82-3.41)	5	2.22 (0.72-5.18)	6	1.58 (0.58-3.43)	<3	0.31 (0.01-1.73)	<3	0.98 (0.02-5.48)	16	4.39 (2.51-7.13)	12	10.38 (5.36-18.13)
	Post-Rituximab	10	1.57 (0.75-2.89)	8	1.77 (0.76-3.48)	4	0.67 (0.18-1.71)	4	0.64 (0.17-1.64)	6	2.13 (0.78-4.63)	59	8.70 (6.62-11.22)	16	7.99 (4.57-12.98)
Rad no	Pre-Rituximab	6	0.58 (0.21-1.27)	5	1.05 (0.34-2.44)	9	1.12 (0.51-2.12)	5	0.74 (0.24-1.74)	<3	0.49 (0.01-2.74)	10	4.07 (1.95-7.49)	9	11.73 (5.36-22.26)
	Post-Rituximab	21	1.15 (0.71-1.76)	22	1.62 (1.02-2.46)	18	1.02 (0.61-1.62)	19	1.05 (0.63-1.64)	17	2.33 (1.36-3.73)	45	8.91 (6.50-11.92)	14	9.64 (5.27-16.18)
Neighborhood SES															
Low	Pre-Rituximab	6	0.79 (0.29-1.73)	4	1.04 (0.28-2.67)	10	1.62 (0.78-2.98)	<3	0.20 (0.01-1.11)	<3	0.64 (0.02-3.56)	5	2.74 (0.89-6.39)	3	5.13 (1.06-14.98)
	Post-Rituximab	11	0.98 (0.49-1.76)	22	2.40 (1.50-3.63)	10	0.90 (0.43-1.66)	9	0.78 (0.36-1.47)	11	2.25 (1.12-4.03)	28	8.98 (5.97-12.98)	11	11.30 (5.64-20.22)
High	Pre-Rituximab	9	1.16 (0.53-2.20)	6	1.87 (0.69-4.08)	5	0.88 (0.28-2.05)	5	1.02 (0.33-2.38)	<3	0.67 (0.02-3.75)	11	6.05 (3.02-10.82)	9	15.77 (7.21-29.93)
	Post-Rituximab	20	1.56 (0.95-2.41)	7	0.83 (0.33-1.71)	10	0.84 (0.40-1.55)	14	1.16 (0.63-1.95)	11	2.21 (1.10-3.96)	27	7.73 (5.09-11.24)	5	5.08 (1.65-11.86)
Latency															
1 to 3 years	Pre-Rituximab	5	0.76 (0.25-1.77)	4	1.38 (0.38-3.54)	4	0.81 (0.22-2.07)	5	1.20 (0.39-2.81)	<3	0.79 (0.02-4.37)	5	3.31 (1.07-7.72)	8	16.22 (7.00-31.95)
	Post-Rituximab	11	1.14 (0.57-2.04)	9	1.30 (0.59-2.46)	9	1.00 (0.46-1.91)	8	0.86 (0.37-1.69)	14	3.69 (2.02-6.20)	21	8.18 (5.06-12.50)	7	8.80 (3.54-18.13)
3 to 5 years	Pre-Rituximab	<3	0.49 (0.06-1.78)	4	2.15 (0.59-5.51)	<3	0.64 (0.08-2.30)	0		<3	1.26 (0.03-7.00)	2	2.09 (0.25-7.56)	<3	3.31 (0.08-18.43)
	Post-Rituximab	7	1.06 (0.43-2.18)	12	2.46 (1.27-4.30)	5	0.78 (0.25-1.83)	6	0.91 (0.34-1.99)	4	1.46 (0.40-3.75)	13	7.18 (3.82-12.28)	4	7.39 (2.01-18.92)
5 to 7 years	Pre-Rituximab	4	1.57 (0.43-4.01)	0		5	2.46 (0.80-5.75)	0		0		7	11.21 (4.51-23.1)	<3	5.11 (0.13-28.47)
	Post-Rituximab	5	1.13 (0.37-2.63)	6	1.82 (0.67-3.95)	<3	0.46 (0.06-1.66)	4	0.90 (0.24-2.30)	<3	1.06 (0.13-3.83)	13	10.37 (5.52-17.73)	<3	5.48 (0.66-19.81)
7+ years	Pre-Rituximab	4	1.89 (0.51-4.83)	<3	1.87 (0.23-6.77)	4	2.29 (0.62-5.86)	<3	0.68 (0.02-3.79)	0		<3	3.63 (0.44-13.11)	<3	12.15 (1.47-43.9)
	Post-Rituximab	8	2.03 (0.88-4.00)	3	1.02 (0.21-2.97)	6	1.55 (0.57-3.38)	5	1.27 (0.41-2.97)	3	1.75 (0.36-5.11)	12	10.42 (5.38-18.20)	3	10.00 (2.06-29.22)
Stage of initial DLBCL															
Local/Regional	Pre-Rituximab	10	1.07 (0.52-1.98)	8	1.83 (0.79-3.60)	13	1.78 (0.95-3.05)	<3	0.17 (0.01-0.92)	<3	0.53 (0.01-2.97)	12	5.31 (2.75-9.28)	6	8.59 (3.15-18.70)
	Post-Rituximab	17	1.32 (0.77-2.12)	14	1.46 (0.80-2.46)	12	0.97 (0.50-1.69)	14	1.10 (0.60-1.85)	10	1.82 (0.87-3.34)	25	6.98 (4.52-10.31)	8	7.46 (3.22-14.69)
Advanced	Pre-Rituximab	4	0.87 (0.24-2.24)	<3	0.99 (0.12-3.59)	<3	0.58 (0.07-2.10)	3	1.01 (0.21-2.96)	<3	1.09 (0.03-6.06)	4	3.82 (1.04-9.79)	4	11.27 (3.07-28.84)
	Post-Rituximab	12	1.22 (0.63-2.13)	14	1.97 (1.07-3.30)	9	0.97 (0.44-1.83)	9	0.92 (0.42-1.75)	9	2.30 (1.05-4.36)	29	10.83 (7.25-15.55)	7	8.99 (3.62-18.53)